Product Description
Mechanisms of Action: ADORA2 Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Ocular, Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Santen
Company Location:
Company Founding Year: 1890
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Glaucoma, Open-Angle|Hypertension
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01279083 |
NCT01279083 | P2 |
Completed |
Hypertension|Glaucoma, Open-Angle |
2011-11-01 |
2019-03-19 |
Recent News Events
Date |
Type |
Title |
|---|